Recruiting Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST NCT06735820 Conditions Atypical Neurofibroma, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fibrosarcoma, +24 more Locations Children's National Hospital — Washington D.C., District of Columbia, United States UT Southwestern Medical Center — Dallas, Texas, United States View Trial Details
Recruiting SPEARHEAD-3 Pediatric Study NCT05642455 Conditions Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neoplasms, +26 more Locations Stanford University — Palo Alto, California, United States National Institutes of Health — Bethesda, Maryland, United States Dana Farber Cancer Institute — Boston, Massachusetts, United States Washington University — St Louis, Missouri, United States View more locations Show fewer locations Loading locations... View Trial Details
Recruiting IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986 Conditions Angiosarcoma, Desmoplastic Small Round Cell Tumor, Fibrosarcoma, +24 more Locations Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China View Trial Details
Completed A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients NCT04811196 Conditions Endometrial Neoplasms, Endometrial Stromal Sarcoma, Endometrial Stromal Tumors, +31 more Locations Princess Margaret Cancer Centre — Toronto, Ontario, Canada View Trial Details
